Biography
I-Jane leads a group of microfluidic engineers and collaborates with internal and external scientists developing products for single cell sequencing and high throughput enzyme screening. She obtained her Ph. D. from University of Tennessee in Biomedical Engineering. Before joining CGI, she worked at Becton Dickson and Caliper Lifesciences.

Genomic Profiling Showcase:
Complete Genomics
A U.S. subsidiary of BGI Group, leading advanced sequencing technologies.

A Handheld, Power-Free Single Cell Sequencing System
iDrop delivers >2000 MEANINGFUL cell genomic information each run in 20 minutes with pollution rate <2%. We will share results collected from various types of samples, including fresh/frozen tissues, live stem cells, and comparison against 10X’s Chromium.

Biography
Hans Cobben is the CEO of BlueBee. He is a serial entrepreneur, seasoned executive, investor and enabler for start-ups and cofounder of a number of globally successful companies. He has held senior executive roles at Alcatel, SunGard and SWIFT. Driven by his experience in technology and excited by the potential of high performance genomics, Hans joined BlueBee as a CEO in 2013.

Genomic Profiling Showcase:
BlueBee
BlueBee empowers visionary companies to accelerate and reimagine life science and precision medicine by enabling rapid scalability, global compliance, and international collaboration. With BlueBee, life science organizations maximize operational efficiency without stifling innovation.

Production-Ready Data Solutions For Technology Providers
Precision healthcare requires computational technologies to cope with the complexity, volume, and security needs of human genomic data. This talk covers a solution for digital health data and metadata for value across the entire delivery chain.

Biography
Prior to founding Cellecta in 2006, Dr. Chenchik was Vice President of R&D at System Biosciences and Director of R&D for the Gene Cloning and Analysis (GCA) group at Clontech Laboratories and Becton Dickinson from 1994 to 2005. Dr. Chenchik received his Ph.D. in Molecular Biology from the Institute of Molecular Biology, Moscow, Russia in 1983, and was a research scientist at the National Cardiology Research Center in Moscow from 1983 through 1994. He has authored over 50 publications and is an inventor on numerous issued patents.

Genomic Profiling Showcase:
Cellecta Inc.
A functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery.

Genetic Phenotypic Screening At A Single-Cell Level
To understand key tumorigenesis mechanisms, novel methods for gene function analysis and phenotypic profiling at a single-cell level have been developed. We will show how genetic screening and targeted RNA expression profiling combined with cell barcoding can significantly improve phenotyping of distinct cell populations.

Biography
Professor Cairns is using systems biology in complex disorders to improve our understanding and identify novel opportunities for treatment. In recent work he has focused on individualized analysis of both genomic and transcriptomic variation to identify opportunities for drug repositioning and precision intervention. He is an NHMRC Senior Research Fellow at the University of Newcastle, Australia. He received his PhD in Biochemistry and Molecular Genetics from the University of New South Wales, Sydney Australia. Professor Cairns was an industry postdoctoral fellow at Johnson and Johnson Research and Nucleics before moving to academic research. Professor Cairns has authored more than 130 publications in various journals and books. His publications reflect his research interests in genomics, bioinformatics, systems biology, pharmacology and precision medicine.

Genomic Profiling Showcase:
University of Newcastle
The University of Newcastle and Hunter Medical Research Institute are highly regarded for health related training, research and clinical translation.

Precision Medicine For Individuals With Complex Disorders Through Pharmacological Annotation Of Their Polygenic Risk
In this talk I will present our informatics framework for quantifying an individual’s common variant enrichment (of complex disorder-associated polygenic risk) in clinically actionable systems. This approach, designated pharmagenic enrichment, facilitates precision medicine by pharmacological annotation of polygenic risk.

Biography
Maggie Rougier-Chapman is the Vice President of Global Marketing at Bionano Genomics. She is a commercial executive with over 15 years of expertise in life sciences, genomics and diagnostics. At Bionano, Maggie is responsible for branding, marketing operations, product management and strategy. She joined Bionano in December 2018 after spending more than 7 years at Agilent Technologies, where she played pivotal roles in sales, sales management and regional marketing management for the Diagnostics and Genomics Division supporting NGS and cytogenetics workflows, CRISPR gene editing, and molecular biology reagents and instrumentation for research and clinical markets. Her career history also includes extensive scientific research, coupled with a variety of business development, sales and marketing responsibilities and achievements from such companies as Stratagene, Incyte Genomics, Cogenics, and Advanced Cell Diagnostics. Maggie holds a Master of Science degree in Molecular Cancer Biology, and a Bachelor of Science degree in Biology with a certificate in Genetics, from Duke University.

Genomic Profiling Showcase:
Bionano Genomics
Bionano Genomics develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new cancer diagnostics and therapeutic targets and to modernize the practice of cytogenetics.

Resolving Structural Variants Across The Genome To Power Discoveries In Cancer & Rare Diseases
Bionano Genomics' Saphyr system is transforming genomics by elucidating genomic rearrangements in cancer and genetic disease that are missed by current methods. Examples will be presented of how Bionano’s genome imaging technology discovers novel fusion genes and complex structural variants that are refractory to NGS and cytogenetics, and how this approach may replace almost all karyotyping, FISH and CNV-microarray assays.

Biography
Dr. Spetzler joined Caris Life Sciences® in August of 2009, and has held several manage¬ment positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the com¬pany’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System®. Under his leadership, the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients, as well as noninvasive technologies to identify and predict early stage cancer. Much of work is focused on the development of the ADAPT Biotargeting System®, a groundbreaking and proprietary method of profiling macro-molecular complexes in their native form in a highly multiplexed format. The innovative technology is the result of the convergence of Caris’ deep expertise in Next-Generation Sequencing, exosome biology, bioinformatics and broad-based molecular profiling.

Genomic Profiling:
Caris Life Sciences
Caris Life Sciences is an innovative biotechnology company, actively working to fulfill the promise of precision medicine through our unique and transformative platforms to help patients with cancer and other complex diseases.

Application Of Next Generation Profiling (NGP) To Molecular Data Sets
Caris NGP, powered by our advanced machine learning platform, DEAN, helps define complex biomarkers that can improve patient outcomes. NGP identifies unique molecular signatures by cancer subtypes, predicts which patients might respond to specific treatments, and improves cancer diagnosis.

Biography
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. He became Chief Medical Officer of Agendia, a molecular diagnostics company specializing in breast cancer genomics, in May of 2016. Prior to joining Agendia, in addition to his clinical practice, he served as Director of the Cedars-Sinai Cancer Center, Clinical Chief of the Division of Hematology/Oncology, and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh was also a faculty member in the Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai and was Associate Clinical Professor of Medicine at the UCLA School of Medicine. Dr Audeh obtained his MD degree for the University of Iowa, MS in Genetics from University of Minnesota, and Internal Medicine and Oncology training at Stanford University.

Genomic Profiling Showcase:
Agendia
From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions.

Genomic Profiling In Early Stage Breast Cancer
Genomic profiling in early-stage breast cancer, provided by Agendia, is expanding beyond the initial chemotherapy/no chemotherapy decision, to now inform other important clinical decisions such as the use of neoadjuvant therapy, systemic drug selection, and surgical decision-making.

Biography
Victoria Reid is the Director of Market Development at 10x Genomics. She has over 15 years of executive management experience in the Healthcare and Life Science Industries. In her role at 10x Genomics, she is focused on building corporate and partnerships with pharmaceutical companies and expanding the use of 10x's platforms into new markets. Prior to 10x Genomics, she worked for some of the top pharmaceutical companies, including Pfizer, Johnson & Johnson, and GlaxoSmithkline.

Genomic Profiling:
10x Genomics
10x Genomics is a leading company in the field of genomics, located in the San Francisco Bay Area with Corporate Headquarters in Pleasanton, CA.

Accelerating Drug Discovery And Development With Single Cell And Spatial Genomics
We will showcase new approaches for single cell and spatial genomics that can be leveraged to accelerate drug discovery and development in multiple disease areas. Through case studies attendees will better understand how these new technologies can be applied opportunistically across different stages of the drug discovery and development pipeline.

Biography
Dr. Mockus is the Director of Product Innovation & Strategic Commercialization at The Jackson Laboratory for Genomic Medicine, where she leads a team disrupting the status quo for interpreting biomedical data. Under her vision and leadership, the organization’s first software product, JAX-CKB, was commercialized. JAX-CKB is a cancer bioinformatics platform used by translational researchers, diagnostic labs, and oncologists across the globe. Her primary focus is on the capture, analysis, and utilization of big-data with AI to disrupt how knowledge is translated from the bench to the bedside. She has over 15-years of industry experience in business development and product innovation.

Genomic Profiling Showcase:
Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution dedicated to contributing to a future of better health care based on the unique genetic makeup of each individual.

Accelerating Interpretation Of Precision Oncology Data With Machine Reading
Implementation of precision oncology requires scalable interpretative tools that address the growing complexity of genetic/genomic data and corresponding treatment modalities. The Clinical Knowledgebase (CKB) leverages Microsoft’s Hanover AI machine-reading technology to provide computer-assisted human curation at scale.

Biography
Dr. Marcin Piechota is a highly educated and experienced bioinformatician with a great knowledge of implementations of novel algorithms and informatics methods into human genomics. He is an engineer in computer science, Java Sun Certified programmer, and SpringSource Certified Professional. Expert in R, Java, Bash and Python. He has started his journey to genomics as a young scientist working in the Institute of Pharmacology Polish Academy of Sciences in Krakow. For several years, he was involved in the research focused on transcriptomics in mouse models of addiction. He was a leader of two scientific projects dedicated to transcriptomics and Chip-seq analyses. The results of his studies were published in Nature, Genome Biology and Stroke. Co-founder of Intelliseq, responsible for the design and development of NGS analytical workflows. His goal is to optimize software development process to improve testability, reliability, reproducibility and portability of genomic workflows and pipelines. At Intelliseq, he leads a multidisciplinary team of computer scientists, bioinformaticians, biologists and physicians.

Biography
Michael is known for his motivational leadership style, the development of trusted relationships and his unique ability to engage talented people. He is dedicated to supporting ambitious goals and long-term strategies for the company, its employees and all of its highly valued partners. Michael has an extensive background in building and fostering the development of technology businesses, including but not limited to, the areas of: Digital Biology, Next-Gen Sequencing, Genomics, and Intercellular Communication. Prior to his role at Cardea Bio, he held leadership positions at CLC Bio, BGI, EXO Incubator, Nanosens, and BlueSEQ.

Genomic Profiling Showcase:
Cardea Bio
Cardea is a next-generation infrastructure company using graphene biosensors, biology and software to transform industries and Connect Life to the Internet.

Reinventing Biology: DNA Search & Biology-gated Transistors
Today, most information is only a few clicks away, but we don’t have access to one of the most fundamental types of information: Our biological information. Cardea’s graphene biosensor infrastructure can detect and convert biological signals to measurable digital information without need for amplification or optics.

Biography
As Chief Scientific Officer, Dr. Chen leads research, development, and clinical efforts at Personalis. He leads a team of bioinformaticians, engineers, scientists, and clinicians developing genomics-based precision medicine solutions in cancer and immuno-oncology. A physician scientist, Dr. Chen has extensive industry experience in immuno-oncology, bioinformatics, systems biology, translational genomics, and product development. Dr. Chen has co-founded and served on the board of several companies, including Ingenuity Systems which pioneered systems biology approaches to genomic data analysis for scientific discovery and data interpretation. Dr. Chen has also served on the clinical faculty at Stanford University School of Medicine where he led process and technology innovation for improved health care delivery. Dr. Chen received a BS in Computer Science, MS in Biomedical Informatics, and a MD from Stanford University and Medical School. He completed his Chief Residency and Dermatology Specialty Training at Stanford and is board certified.

Enabling Integrative, Composite Biomarkers For Cancer Diagnostics And Therapy

Biography
Radhakrishna Bettadapura, or RK, heads business development at Strand Life Sciences. RK"s background is in life sciences and engineering, and his expertise spans computational biology, bioinformatics, and business operations.

Genomic Profiling Showcase:
Strand Life Sciences
Strand Life Sciences is a precision medicine company based in Bangalore, India.

A Saliva-based Liquid Biopsy NGS Test For The Early Detection Of Oral Cancer
At Strand, we've developed a framework to address biological questions in the clinic. The framework, consisting of clinical recruitment, laboratory measurements, and data analysis, is being applied to a variety of data and biology-heavy problems by translational groups in pharma and academia. In this context, we present a ctDNA assay for the early detection of oral cancer from saliva. This is joint work with the University of Chicago.